Saturday 17 October 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.3%, EPS grew 40.7% and free cash flow grew 33.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.03
0.04
−3.74%
Follow LSTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (101.66%) | (91.41%) | (75.53%) | (72.17%) |
+8 more TTM periods Free account |
|
| (80.81%) | (75.98%) | (62.89%) | (60.85%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(181.85%) | (152.51%) | (113.22%) | (107.12%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.35) | (1.51) | (1.84) | (1.98) | |
Free Cash Flow |
(12.32) | (13.63) | (15.98) | (17.28) | |
Capital Expenditures |
— | — | (0.03) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(66.85%) | (57.43%) | (52.29%) | (47.85%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | (0.27) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 52.23% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 68.53% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 8.06% | 0.00% | |
Operating CF/Net income |
0.84 | 0.83 | 0.96 | 0.94 | |
Depreciation/Fixed assets |
3.57 | 4.44 | 3.94 | 0.82 | |
Capex/Depreciation |
0.00 | 0.00 | (0.39) | (3.00) | |
Revenue per Share |
0.00 | 0.00 | 1.75 | 0.00 | |
Operating CF per Share |
(1.35) | (1.51) | (1.84) | (1.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates